PRKAA2 and COVID-19: This context-specific requirement of AMPK for Treg cell function makes it an attractive drug target for attempts to potentiate the function of Treg cells ex vivo before their use in cell-based therapies, such as those being leveraged in early phase clinical trials to improve outcomes in patients with COVID-19 (58, 59).